Impact Therapeutics, Inc.
18
3
4
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
6%
1 trials in Phase 3/4
0%
0 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Role: collaborator
Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer
Role: lead
A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Role: lead
A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects
Role: lead
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition
Role: lead
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition
Role: lead
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Role: collaborator
A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State
Role: lead
An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition
Role: lead
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Role: lead
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Role: lead
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
Role: lead
Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment
Role: lead
IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers
Role: lead
BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects
Role: lead
The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
Role: lead
A Study of IMP4297 in Patients With Advanced Solid Tumors
Role: lead
IMP4297 Food Effect Trial in Healthy Volunteers
Role: lead
All 18 trials loaded